Tildrakizumab
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Tildrakizumab: From Plaque Psoriasis to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Tildrakizumab is an anti-IL-23p19 monoclonal antibody originally approved for plaque psoriasis. The TxGNN model predicts it may be effective for Severe Nonproliferative Diabetic Retinopathy, but currently no clinical trials and no publications support this direction — this is a model-only prediction (L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Plaque psoriasis (drawn from mechanism-of-action context; no formal license record on file) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal mechanism-of-action data for Tildrakizumab is not available in the structured drug record. Based on the evidence gathered in this analysis, however, Tildrakizumab is known to be an anti-IL-23p19 monoclonal antibody that suppresses the Th17 inflammatory pathway, and it is approved for plaque psoriasis.
Because IL-23/Th17 signaling has a theoretical role in inflammatory microvascular pathology, TxGNN’s knowledge graph links the drug to several diabetes-related complications — severe nonproliferative diabetic retinopathy, diabetic retinopathy, diabetic cataract, and drug-induced osteoporosis. Of these four, drug-induced osteoporosis has the most defensible biological rationale (Th17/IL-23 can drive RANKL-mediated osteoclast activation, an established osteoimmunology pathway), while the retinopathy and cataract predictions appear to rely on indirect “inflammation–vascular disease” node adjacency in the graph rather than drug-specific mechanistic evidence.
No pharmacokinetic data confirm whether a systemically administered monoclonal antibody achieves meaningful intraocular penetration, and no clinical trials or literature currently support any of these four indications. All four should be treated as hypothesis-generating signals only, not as evidence-backed repurposing candidates.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: internal data gap tracking flags TFDA label warnings/contraindications as a Blocking gap — this must be resolved before any safety review can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: All four TxGNN-predicted indications (including the top-ranked severe nonproliferative diabetic retinopathy) are supported only by model score, with zero clinical trials or literature and no confirmed MOA/safety documentation. This does not meet the minimum evidence threshold to advance past S0.
To proceed, the following is needed:
- Formal TFDA/manufacturer label data — warnings, contraindications (Blocking gap, DG001)
- Confirmed mechanism-of-action documentation (DG002)
- Preclinical or mechanistic literature specifically linking IL-23 inhibition to diabetic retinopathy, diabetic cataract, and drug-induced osteoporosis
- Ocular pharmacokinetics/bioavailability assessment for systemic monoclonal antibody administration
- If evidence accrues, prioritize the drug-induced osteoporosis indication given its comparatively stronger osteoimmunology rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.